Mason, John O <br/><br/>
Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection.  [electronic resource] 

 -  Retina (Philadelphia, Pa.)  Apr 2008 
 - 564-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0275-004X 
<br/><br/><label>Standard No.: </label>10.1097/IAE.0b013e3181633fee  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Disease<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--administration & dosage<br/>Anti-Bacterial Agents--therapeutic use<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Bevacizumab<br/>Choroidal Neovascularization--drug therapy<br/>Drug Therapy, Combination<br/>Endophthalmitis--drug therapy<br/>Eye Infections, Bacterial--drug therapy<br/>Female<br/>Humans<br/>Incidence<br/>Injections--adverse effects<br/>Macular Degeneration--drug therapy<br/>Risk Factors<br/>Staphylococcal Infections--drug therapy<br/>Staphylococcus--isolation & purification<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity<br/>Vitreous Body--microbiology